



Agenda  
MedTech Task Force  
The Corporation of the City of Brampton

**Date:** Thursday, November 7, 2024

**Time:** 4:00 p.m.

**Location:** Hybrid Meeting - Virtual Option & In-Person in Council Chambers – 4th Floor – City Hall

**Members:** Deputy Mayor H. Singh (Chair)  
Dr. Mohamed Lachemi, President, Toronto Metropolitan University (Vice-Chair)  
Regional Councillor M. Palleschi - Wards 2 and 6  
Regional Councillor R. Santos - Wards 1 and 5  
Regional Councillor G. Toor - Wards 9 and 10  
Tony Chahine, CEO, Myant Inc.  
Vito Ciciretto, President and CEO, Dynacare  
Jason Field, President and CEO, Life Sciences Ontario  
Anton Katipunan, Development with RioCan, RioCan  
Brian Leahy, Director, External Community Relations, Algoma University  
Dr. Frank Martino, President & CEO, William Osler Health Systems  
Jailpaul Massey-Singh, CEO, Brampton Board of Trade  
David Moores, Vice president, Development Engineering, Orlando Corporation  
Dr. Dante Morra, Chief of Medical Staff, Trillium Health Partners  
Dr. Janet Morrison, President & Vice Chancellor, Sheridan College  
Peter Nikolakakos, Executive Vice President, Development & Planning, First Gulf  
John Sincerbox, Medtronic Canada  
Carl Rodrigues, CEO, SOTI  
Ken Spears, General Manager / Vice-President, Boston Scientific Canada  
Darren Steedman, Vice-President, DG Group  
Jay Stevens, CEO, The Stevens Company  
Amy Swanson, Vice-President, MedTech Canada  
Andreas Wegner, General Manager, Taro Pharmaceuticals  
Mahes Wickramasinghe, EVP & Chief Administrative Officer, Rogers  
Vincci Wilson, VP Development, NorthWest Healthcare Properties REIT  
Blair Wolk, President, Orlando Corporation  
David Wyatt, Senior Vice President, Morguard Investments Ltd

For inquiries about this agenda, or to make arrangements for accessibility accommodations for persons attending (some advance notice may be required), please contact:  
Tammi Jackson, Legislative Coordinator, Telephone 905.874.3829, TTY 905.874.2130  
[cityclerksoffice@brampton.ca](mailto:cityclerksoffice@brampton.ca)

Note: Meeting information is also available in alternate formats upon request.

---

1. Call to Order

2. Approval of Agenda

3. Declarations of Interest under the Municipal Conflict of Interest Act

4. Previous Minutes

The minutes were considered by Committee of Council on June 26, 2024, and were approved by Council on July 10, 2024. The minutes are provided for Committee's information.

5. Presentations / Delegations

5.1 Opening Remarks by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU).

5.2 Presentations by Stakeholders:

1. William Osler Health System

- Dr. Greg Rutledge, Chief of Staff; Tiziana Rivera, Executive VP, Quality and Research

To be distributed prior to the meeting.

2. Ontario Centre of Innovation

- Jeff Van Heumen, Assistant Vice-President, Business Development

To be distributed prior to the meeting.

*To be received.*

6. Other / New Business / Information Items

6.1 Follow-up on Key Projects:

1. Wet Labs – Feasibility Study / Consultation Update

- Daniel Lacey, AVP, CBRE Life Sciences; Ross Wallace, Principal, Santis Health

*To be received.*

6.2 MedTech Task Force - 2025 Meeting Schedule

*To be received.*

7. Member Questions / Roundtable

8. Correspondence

9. Question Period

10. Public Question Period

**15 Minute Limit (regarding any decision made at this meeting)**

11. Adjournment

Closing Remarks by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU).

**Next Scheduled Meeting:** Thursday, April 24, 2025, at 4:00 p.m. in the Council Chambers at Brampton City Hall.

**Note:** Refreshments and networking for Task Force members and invited guests will be held in the Council Lounge following the meeting.



## Minutes

### MedTech Task Force

### The Corporation of the City of Brampton

**Thursday, May 30, 2024**

- Members Present:
- Deputy Mayor H. Singh (Chair)
  - Dr. Mohamed Lachemi, President, Toronto Metropolitan University (Vice-Chair)
  - Regional Councillor R. Santos - Wards 1 and 5
  - Dave Casimiro, Managing Director, NorthWest Healthcare Properties REIT
  - Vito Ciciretto, President and CEO, Dynacare
  - Sheri Dodd, President, Medtronic Canada
  - Jason Field, President and CEO, Life Sciences Ontario
  - Jaipaul Massey-Singh, CEO, Brampton Board of Trade
  - Dr. Frank Martino, President & CEO, William Osler Health Systems
  - Dr. Janet Morrison, President & Vice Chancellor, Sheridan College
  - Jay Stevens, CEO, The Stevens Company
  - Amy Swanson, Vice-President, MedTech Canada
  - Andreas Wegner, General Manager, Taro Pharmaceuticals
  - Vincci Wilson, VP NorthWest Healthcare Properties REIT
  - Mahes Wickramasinghe, EVP & Chief Administrative Officer, Rogers
  - David Wyatt, Senior Vice President, Morguard Investments Ltd
  - Deepak Sharma, William Osler Health Systems (Alternate)
- Members Absent:
- Regional Councillor M. Palleschi - Wards 2 and 6
  - Regional Councillor G. Toor - Wards 9 and 10
  - Tony Chahine, CEO, Myant Inc.
  - Anton Katipunan, Development with RioCan, RioCan
  - Brian Leahy, Director, External Community Relations, Algoma University
  - David Moores, Vice President, Development Engineering, Orlando Corporation

Dr. Dante Morra, Chief of Medical Staff, Trillium Health Partners  
Peter Nikolakakos, Executive Vice President, Development &  
Planning, First Gulf  
Carl Rodrigues, CEO, SOTI  
Ken Spears, General Manager / Vice-President, Boston  
Scientific Canada  
Darren Steedman, Vice-President, DG Group  
Blair Wolk, President, Orlando Corporation

---

1. **Call to Order**

The meeting was called to order at 4:08 p.m. and adjourned at 5:39 p.m.

2. **Approval of Agenda**

The following motion was considered.

**MTTF001-2024**

That the agenda for the MedTech Task Force Committee Meeting of May 30, 2024, be approved as published and circulated.

Carried

3. **Declarations of Interest under the Municipal Conflict of Interest Act**

Nil

4. **Previous Minutes**

The minutes were considered by Committee of Council on November 29, 2023, and were approved by Council on December 6, 2023. The minutes were provided for Committee's information.

5. **Presentations / Delegations**

5.1 Presentation by Stakeholders:

1. Algoma University
  - Dr. Istvan Imre
2. Roga Life
  - Dr. Alison Smith, Co-Founder and Chief Scientist
3. Medical Alley, MN
  - Frank Jaskulke

Dr. Istvan Imre, Algoma University, provided a brief overview of the company that included the following:

- Two initiatives being implemented:
  - Ontario Mental Health & Addictions Research Training Institute (OMHARTI) at the Sault Ste. Marie and Brampton locations
  - National Centre of Excellence in Immersive Technology partnering with Unity.
- Outlined the purpose and goals of OMHARTI.
  - Brampton location - 145 Queen Street East - newly leased independent building.
  - The facility will host undergraduate and graduate programming in the areas of Psychology and Social Work.
- The National Centre of Excellence (CoE) in Immersive Technology focuses on bridging the divide between the augmented reality.
  - Outlined the vision and mission of the initiative.
  - CoE Pillars - Education Advancement and Skill Development; Innovation and Industry collaboration; Community Integration and Outreach.

Dr. Alison Smith, Co-Founder and Chief Scientist, Roga Life, provided a brief overview of the company that included the following:

- Roga Life is an early stage MedTech startup that is part of the Brampton Venture Zone.
- Mental healthcare platform to treat employee stress, anxiety and burnout.
- Sells corporate health benefits.
- Since the pandemic stress and anxiety have significantly increased, especially for those within the workforce.
  - 72 percent of employees are experiencing intense stress resulting in performance decline, absenteeism, turnover and medical expenses.
  - To deal with such anxieties people only have access to talk therapists and medication.
  - Looking for MedTech solutions to assist individuals wherever they are.



- Mental Healthcare Platform - wearable device (effectively reduces stress and burnout) and AI guided meditations (personalized guided meditations and treatment progress analytics).
- Currently on the market as a "wellness device" for intense stress and burnout.
- Future goal is to achieve "Medical Device Status" to treat anxiety.

Frank Jaskulke, Medical Alley, MN, provided a brief overview of the company that included the following:

- Not-for-profit trade association.
- Outlined the company's mission and vision.
- Partnership services: connections, advocacy, insights, engagement.
- Foundational and sustaining partners.
- Medical Alley Board of Directors
- Strategic Value Creation - four core initiatives: Medical Alley Starts, Medical Alley Global, Healthcare Transformation Initiative (HTI) and Local and Federal Policy.
- Strategic Initiatives: enabling healthcare innovation, elevate business progress, transform health equity.

The following motion was considered.

**MTTF002-2024**

That the following presentations to the MedTech Task Force Committee Meeting of May 30, 2024, re:

1. **Algoma University**
2. **Roga Life**
3. **Medical Alley, MN**

be received.

Carried

## 6. Other / New Business / Information Items

The following motion was considered.

### 6.1 Updates:

1. The Brampton Medical School
  - Dr. Mohamed Lachemi
2. Update from the Brampton Venture Zone
  - John MacRitchie and Fardan Khan

Dr. Mohamed Lachemi, President, Toronto Metropolitan University (TMU), provided an update on the Brampton Medical School that included:

- On track to welcome the first group of medical learners in 2025:
  - 105 residents (July 2025 Intake)
  - 94 MD students (September 2025 Intake)
- Clinical affiliations will ensure the delivery of high-quality placements and celebrate primary care.
- Integrated Health Centre (IHC) will increase primary care access.
- Accreditation process is proceeding on schedule.

John MacRitchie and Fardan Khan, Brampton Venture Zone, provided a brief update on the Brampton Venture Zone that included the work undertaken to date and the work that is upcoming for 2025.

The following motion was considered.

### **MTTF003-2024**

That the following updates to the MedTech Task Force Committee Meeting of May 30, 2024, re:

1. **Brampton Medical School**
2. **Brampton Venture Zone**

be received.

Carried

## 6.2 Follow-up on Key Projects:

1. Wet Labs - Outline of Feasibility Study / Consultation
  - Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton
2. The MedTech Conference, Toronto - October 15 - 17, 2024
  - Amy Swanson
  - Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton
3. Other Items - Sector MedTech Outline (new) with Our Stakeholders (Including BIO 2024)
  - Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton

Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the Wet Lab - Feasibility Study/Consultation.

Amy Swanson, Vice-President, MedTech Canada and Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the subject matter that included the following:

- Four pillars of the conference: Networking, education program, partnering and investor forum and the MedTech campus.
- Flexpass Campaign
- Registration rates.
- All-access pass includes: four days of education, networking, access to the Medtech campus, and partnering with thousands of Medtech innovators.
- Partnered with Destination Toronto at the conference and will be at booth 700.
- Deputy Mayor Singh and Councillor Toor will be available on October 17th for half a day.
- Looking at setting up a panel discussion at the booth.

Martin Bohl, Sector Manager, Health & Life Sciences, Office of the Chief Administrative Officer, City of Brampton provided an update on the subject matter that included the following:

- Looking to update the marketing panel.
- Change the narrative and look at our research, startup companies.
- Asking for input or key items to showcase moving forward into 2025.

The following motion was considered.

**MTTF004-2024**

That the following Verbal Updates on Key Projects to the MedTech Task Force Committee Meeting of May 30, 2024, re:

1. **Wet Labs - Outline of Feasibility Study/Consultation**
2. **MedTech Conference, Toronto - October 15 - 17, 2024**
3. **Sector MedTech Outline (new) with Our Stakeholders (Including BIO 2024).**

be received.

Carried

6.3 Information Item re: Concept for a 2025 Conference in Brampton –Brain Injury Association Peel Halton, Nick Kuryluk and Sarah Diaz

Nick Kuryluk and Sarah Diaz, Brain Injury Association Peel Halton provided information regarding the Concept for a 2025 Conference in Brampton and advised they were seeking the Committee's support and financial backing to secure the Rose Theatre for a one-and-a half to two-day conference in 2025.

The following motion was considered.

**MTTF005-2024**

That the presentation from Sarah Diaz, Brain Injury Association, Peel Halton, re: Concept for a 2025 Conference in Brampton, to the MedTech Task Force Committee Meeting of May 30, 2024, be received.

Carried

7. **Member Questions / Roundtable**

Nil

8. **Correspondence**

Nil

9. **Question Period**

Nil

10. **Public Question Period**

Nil

11. **Adjournment**

Closing Remarks were provided by Deputy Mayor Singh and Dr. Mohamed Lachemi, President of Toronto Metropolitan University (TMU).

The following motion was considered.

**MTTF006-2024**

That the MedTech Task Force do now adjourn to meet again for a Regular Meeting of Committee on Thursday, November 7, 2024 at 4:00 p.m. or at the call of the Chair.

Carried

---


Deputy Mayor H. Singh (Chair)

---

Mohamed Lachemi (Vice-Chair)

TORONTO

Brampton's Key  
Partners and  
Collaborators:

 William Osler  
Health System

 INVEST BRAMPTON







ONTARIO  
CANADA  
YOUR MEDTECH PARTNER

TORONTO

THE MEDTECH  
CONFERENCE  
KEYNOTE  
THEATRE  
ENTRANCE

Australia

HAMILTON

chs  
Your Partner in Customized  
Healthcare Solutions.



# TORONTO

9:00AM – 10:00AM  
▶ BRAMPTON'S START-UP ECOSYSTEM

MODERATOR  
**MARKIRAT SINGH**  
City Mayor, City of Brampton

MODERATOR  
**ARTAP SINGH TOOR**  
City of Brampton

**ON SMITH**  
and Co-founder

**IK BISWAS**  
Tenomix



IB. IN RESEARCH  
D DEVELOPMENT

# Identifying the Needs for Lab Space in Brampton

November 7, 2024

# Study Goals

---

CBRE, in partnership with Santis Health, conducted a feasibility study **to assess lab space demand for the life science sector in Brampton.**

This feasibility study aims to **identify the market demand for lab space, opportunities for partnerships, and the ideal composition of ecosystem players to create a thriving lab environment in Brampton** that supports the growth of institutional players, collaboration with industry partners, and development of early-stage companies through a collaborative life sciences community.

This work will support the City of Brampton in:

- Providing insights to help start-up retention in Brampton and Ontario
- Acknowledging investments (past and future) in its Innovation District
- Help develop talent for growing firms
- Enhancing Brampton's role in Ontario Life Sciences Strategy growth

This study provides insights using **two approaches:**

- 1) Ecosystem Analysis
- 2) Real Estate Analysis

# Study Approach: (1) Ecosystem Analysis



## Semi-structured interviews:

1-hour semi-structured **interviews.**

**Target groups:** Government, Healthcare, Academia, Industry, Ecosystem Partners

**27** Completed Interviews

**1** Scheduling in Progress

**2** Declined / Non-Responsive Interviews

We provided interviewees with overall questions in advance.

### **Overall interview questions:**

1. *What is the current state of lab space in Brampton?*
2. *Do you feel Brampton has the pieces/components for a thriving life sciences ecosystem?*
3. *What is the optimal location for new lab space in Brampton?*
4. *What would success look like for lab space in Brampton in 2-5 years?*

# Stakeholders Engaged

Government (n=3), Academia (n=4),  
Industry (n=11), Ecosystem partners (n=9)



Ministry of Economic  
Development, Job  
Creation and Trade



# Study Approach: (2) Real Estate Analysis



## Assessing the Demand

Determine the estimated **demand for laboratory space** and evaluate its **viability**.

- 1) Market outreach through CBRE's proprietary "Tenants in the Market" list
- 2) Establish any demand from key local institutions and assess their needs



## Location intelligence

To identify the **ideal location for a thriving life science asset** we analyzed the following criteria:

- 1) Demand and industry clusters
- 2) Transportation and accessibility
- 3) Proximity to skilled workforce and ideation
- 4) Partnership and collaboration opportunities

# Our Research Generated 5 Key Insights

---

1. Many Stakeholders Possess a **General Awareness of Brampton's Advantages...BUT Knowledge** of Brampton's Specific Innovation Assets **is Insufficient and Incomplete**
2. Brampton Has the **Critical Mix of "Anchor Institutions"** Required to Support a Thriving Ecosystem and **Strengthening Those Institutional Ties** Will Be Critical to Future Growth
3. **MedTech** is Brampton's **Area of Greatest Opportunity**, while Start-Ups and SMEs Need **Space AND Services**
4. **Phase II of Ontario's Life Sciences Strategy** Comes at the Perfect Time
5. Brampton Has a Number of **Logical Development Sites**

# 1. Many Stakeholders Possess a General Awareness of Brampton's Advantages...BUT Knowledge of Brampton's Specific Innovation Assets is Insufficient and Incomplete

- **Brampton's location**, in the Toronto and Kitchener-Waterloo corridor, makes it attractive for medical innovation and talent access.
- Brampton offers **more affordable real estate** compared to neighbors.
- **Close proximity to key partners** enables engagement among healthcare professionals, academic institutions, and startups.
- Significant **political will** exists in Brampton to develop the life sciences sector.
- However, many stakeholders outside Brampton are **uninformed about its strengths and unsure** what differentiates the city in this sector.

*Physical proximity is key in the context of how you sort of package it together and don't create an island unto yourself ...but leverage it*

*Brampton has political will, it is a less tangible piece but that is huge. It's really important because that would accelerate the development of this.*

*I was doing some Googling to try and understand if there was any sort of centralized repository of assets that are available but I could not find it*

*I know the medical school is coming but other than that, no.*



## 2. Brampton Has the Critical Mix of “Anchor Institutions” Required to Support a Thriving Ecosystem and Strengthening Those Institutional Ties Will Be Critical to Future Growth



**Partnerships** with key stakeholders are essential for driving innovation and providing resources.



**Medical and academic institutions** can provide resources, such as Principal Investigators (PIs) and access to patient populations for preclinical studies.



**Existing collaborations** between startups, hospitals, and research institutions need better integration to provide access to lab spaces, product validation, and equipment.



The need for streamlined processes in place was emphasized for a successful collaboration in Brampton.

“

*It would be great if the city would work collaboratively with the medical school to try to get funding from the FedDev regional development innovation program.*

”

“

*The medical school at TMU would be a great collaborative partner so that clinicians at the Med school would be on site as PIs to help access the patient population.*

”

“

*Success looks like an integrated partnership with hospital researchers and the industry working together to achieve the impossible. To improve the health of the Brampton community through partnership, through collaboration, through an integrated approach, rather than everybody working in their own buildings with their own interests.*

”

“

*There needs to be more of a streamlined pathway that makes sense so that it's a bit less segregated*

”

### 3. MedTech is Brampton's Area of Greatest Opportunity, while Start-Ups and SMEs Need Space AND Services



**Brampton's medtech sector as its key strength in contrast with the biotech sector.**

- There is currently **no incubator or accelerator** in the region for MedTech companies in areas such as **quality management systems and regulatory needs**.
- Biotech potential exists in oncology and mental health, supported by clinical research **capabilities at William Osler**.



**Companies need space and services**

- Early-stage MedTech companies in Brampton **need clear processes and guidance** to navigate **commercialization**.
- There is a lack of **high-caliber mentors and regulatory advice**.
- Startups struggle with **funding for pre-clinical trials and pilot studies**, making it difficult to enter new ecosystems effectively.

“  
*If Brampton decides to take a Medtech angle, they have to make sure it's complementary to whatever neighbors are doing. It is important to recognize what's their strength.*  
”

“  
*It might be that a coalition of those big medtech companies in Brampton gets formed.*  
”

“  
*So far we haven't had access to that caliber of mentor. We're looking for mentors that have been in the Medtech space for Class 2 devices.*  
”

“  
*The problem is to commercialize the technology, and commercialize an idea requires a very different skill set. Research groups are usually not good at that.*  
”

## 4. Phase II of Ontario's Life Sciences Strategy Comes at the Perfect Time

October 15, 2024: Announcement of **Phase II of Life Sciences Strategy**

- The Strategy focuses on promoting innovation, increasing investments, and advancing research to strengthen the province's position as a global leader in biomanufacturing and health sciences.
- The Strategy came with an **investment of \$146 million**. Some of the investments include:
  - Up to **\$46 million** for the Ontario Biosciences Research Infrastructure Fund, to help **boost research capacity** at **academic institutions and research hospitals**.
  - **\$15 million** for a new wet labs program to make it easier for companies to **access lab spaces**.
  - **\$40 million** from the Venture Ontario Fund to **support venture capital for Ontario-based life sciences companies and biomanufacturers**.
- Phase II promises a **new Health Innovation Pathway**, aimed to **streamline and simplify access** for health care organizations **to adopt groundbreaking technologies** with the priority to support Ontario-based innovations.

# Real Estate Analysis - Assessing the Demand (I)

CBRE entered into the project with an expectation that the commercial demand it had been tracking throughout the GTHA would not justify a new lab development in Brampton. While that assumption wasn't proven to be wrong, **we found something that proved to be far more critical.**



118 active tenant requirements were surveyed on both their requirement status and asked the question of “**what about Brampton**” ....unsurprisingly, **results were mixed**



General sentiment was **a desire to stay close to where the company was founded** due to existing employee bases and founder participation in ongoing institutional work, however, 37% of respondents indicated that they would consider making the **move to Brampton if the lab space and support services they require exist there**



It should be noted that these companies are generally looking for turnkey space and don't have the capital for build-outs, budget for market rent based on cost, nor **covenants that would be deemed “bank financeable”**

The question that needed to be answered was whether or not the type of tenant demand that can support the underwriting of a new development existed. We found that the **viable institutional demand to support a development pro forma seems to exist from within Brampton**.....the question then is, how do we bring that together?

## Real Estate Analysis - Assessing the Demand (II)

As mentioned, the project initially assumed that lab demand external to Brampton was the key factor to growing the sector, however, the City needs to **build the environment that not only attracts, but more importantly, fosters from within**...building this starts with the needs of the institutional anchors.



Early indications for the new school of medicine are that it will be focused on training clinical staff...**TMU needs to have innovation planned into that facility**



**WOH needs to expand their research operations** and if this can be done as part of a multi-tenanted facility, this would be a catalyst for innovation and collaboration



Both the location and space needs at BVZ are under consideration...**if lab space was accessible, it would support start-up programming and provide a key component in the “suite of services”**




Both **Algoma University and Sheridan College are expanding** science programming and could be a piece of the puzzle

**Fostering a research partnership between academia and WOH** will develop IP and new companies. Ensuring local **academic institutions develop talent** to support both healthcare research and large-local industry needs, will grow the existing employment base in Brampton.

# Real Estate Analysis - Location Intelligence



After extensive stakeholder engagement, the sentiment was clear as to the corridor of innovation and opportunity for lab assets to support sector growth.



“The proximity to universities, hospitals, and transit hubs (like GO Transit and the upcoming LRT) should play a key role in determining the location for a life sciences development”

## 5. Brampton has a Number of Logical Development Sites

The clustering of research significantly impacts the proclivity for innovation and Brampton's foundational building blocks are the gravitational pull for future laboratory assets, **making the Queen St corridor between downtown and Bramalea Civic Centre the key area of interest.**



Downtown possesses the “B-Ecosystem” in the Innovation District, including the BEC, BVZ and B-Hive, as well as the presence of **Algoma University and their continued expansion** into health sciences



The **land on Queen Street directly in front of Peel Memorial Hospital and William Osler's research operations** presents a great opportunity to have clinical services at your doorstep



The **TMU Medical School at Bramalea Civic Centre** presents an opportunity for ideation to turn into IP if innovation is part of the programming

**All three areas present strengths from an ecosystem building standpoint,** but possess development hurdles that would need to be overcome for a project to advance.

# What a Successful Outcome Looks Like

Two phases of development are required in a long term vision:

Phase 1 should be a multi-tenanted facility which brings academic and healthcare research together and will give organic IP and early stage companies a place to germinate

Phase 2 would be a larger facility where companies can expand when they've outgrown the phase 1 facility

“An integrated partnership between institutional researchers and industry, working together to achieve the impossible. So, whether it be cures, drugs or medical devices, improve the health of the Brampton community through partnership, through collaboration, through an integrated approach, rather than everybody working in their own buildings with their own interests.”

## Phase 1- Stacking Plan





# Preliminary Recommendations

## Overview

Our recommendations are clustered into 3 broad buckets:

### Funding

- 1) Work with supporters at Queen's Park to ensure that Phase II of Ontario's Life Sciences Strategy is flexible enough to accommodate the engineering and "dry labs" the Medtech sector needs - not just the "wet labs" required by biopharma start-ups.
- 2) Identify existing and new opportunities to access funding from FedDev, based on the agency's previous investments in life sciences.

### Partnerships and Programs

- 3) Develop an integrated marketing platform that highlights the Brampton ecosystem - and clearly communicates how to access its key institutions, assets and initiatives.
- 4) Collaborate with Brampton's anchor institutions - including WOH, TMU, Algoma, and Sheridan - to foster the growth of early-stage companies by providing support with pre-clinical validation, clinical trials, access to animal facilities, mentorship, and regulatory consultation.

### Infrastructure

- 5) Work with anchor institutions to determine their ability to integrate their future programming into a new facility that includes incubation space with the necessary physical traits and suite of services including partnerships for the start-up community to accelerate their commercialization process.
- 6) Encourage institutional labs and research requirements to come together in a collaborative, multitenant facility along the Queen Street Corridor. CBRE recommends the vacant land in front of Peel Memorial Hospital or downtown Brampton for any new build site, or, if possible, within the TMU Medical School if there is excess space that has yet to be programmed.

**Thank you.**

## MedTech Task Force

All meetings commence at 4:00 p.m. and will be hybrid (virtual and in-person) in the Council Chambers – 4 the Floor, City Hall  
*(Location and format of the meeting will be noted on the agenda)*

Meeting Dates
April 24, 2025
November 13, 2025

**Members:** If you are unable to attend a meeting, please contact Tammi Jackson, Legislative Coordinator, via email at [tammi.jackson@brampton.ca](mailto:tammi.jackson@brampton.ca) at your earliest possible convenience.